Venus Remedies Receives Marketing Authorization for Anticoagulant ‘Enoxaparin’ in Indonesia

Mumbai: Venus Remedies Limited, a leading Indian exporter of generic drugs, has received marketing authorization from Indonesia for its Enoxaparin in pre-filled syringes across all major strengths.

This approval reinforces the company’s presence in Indonesia, Southeast Asia’s largest pharmaceutical market, and aligns with its broader expansion strategy in the region.

Enoxaparin, a key anticoagulant, helps prevent and treat blood clots, reducing the risk of deep vein thrombosis and pulmonary embolism. The global Enoxaparin market is projected to reach USD 5.4 billion by 2032, growing at a CAGR of 7.1%-7.9%.

Venus Remedies is well-positioned to capture a significant market share in Southeast Asia and beyond, with an annual production capacity exceeding 10 million units at its autonomous robotic facility.

The Southeast Asian anticoagulant market is expected to reach USD 550.7 million by 2029, growing at 7.84% CAGR, while Indonesia’s market alone is projected to expand at 7.72% CAGR, reaching USD 140.3 million by 2029.

This development strengthens Venus Remedies’ commitment to advancing accessible healthcare solutions, with over a dozen global marketing authorizations for Enoxaparin.